Barclays maintains Alnylam Pharmaceuticals at Overweight, lowers price target to $380 from $450
Barclays kept Alnylam Pharmaceuticals at Overweight, cutting its price target to $380 from $450, a 15.6% reduction. This implies a 158.2% upside from the Oct 30 close of $147.17. Recent analyst targets for the company range from $199 to $354.
How this was made
The 30-second read
Why it matters
The downgrade may prompt short-term selling pressure but does not indicate a fundamental shift in the company's business.
Market read
A modest analyst target cut for ALNY, likely causing limited price movement.
What to watch
Potential pipeline milestones or partnership news not covered in the article could offset the target reduction.
Background
Barclays' analyst team adjusted its valuation for Alnylam Pharmaceuticals, reflecting a more conservative outlook.
Ticker impact
Barclays lowered its price target on Alnylam Pharmaceuticals to $380 from $450, a new analyst rating change.
likely downward pressure as investors reassess valuation
Target reduction is a fresh analyst action, but the magnitude is modest and does not involve material corporate events.
Market effects
May slightly temper sentiment in the biotech sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
The target cut could be an overreaction; the stock may still have upside if upcoming trial data are positive.
Key entities
- AnalystBarclays
Equity research firm providing the price target revision.
- CompanyAlnylam Pharmaceuticals
Biotech firm developing RNAi therapeutics.
